Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis

Feast or famine in multiple sclerosis therapeutics

(2020) Robert J Fox   LANCET NEUROLOGY

Confounding effect of blood volume and body mass index on blood neurofilament light chain levels

(2020) Ali Manouchehrinia et al.   Annals of Clinical and Translational Neurology

Serum neurofilament light as a biomarker in progressive multiple sclerosis

(2020) Raju Kapoor et al.   NEUROLOGY

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

(2019) Jens Kuhle et al.   NEUROLOGY

Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case–control studies

(2019) Sarah-Jane Martin et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology

(2019) Claire Bridel et al.   JAMA Neurology

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

(2018) Christian Barro et al.   BRAIN

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

(2018) Raju Kapoor et al.   LANCET NEUROLOGY

CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage

(2018) Jeppe Romme Christensen et al.   Multiple Sclerosis Journal

CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage

(2018) Jeppe Romme Christensen et al.   Multiple Sclerosis Journal

Serum Neurofilament Light Chain Levels Are Related to Small Vessel Disease Burden

(2018) Marco Duering et al.   Journal of Stroke

Neurofilaments as biomarkers in neurological disorders

(2018) Michael Khalil et al.   Nature Reviews Neurology

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

(2018) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

(2017) Lenka Novakova et al.   NEUROLOGY

Plasma neurofilament light chain levels in Alzheimer’s disease

(2017) Wenjun Zhou et al.   NEUROSCIENCE LETTERS

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis

(2016) Robert J. Fox et al.   Contemporary Clinical Trials

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials

(2013) Maria Pia Sormani et al.   LANCET NEUROLOGY

Neurofilaments as biomarkers in multiple sclerosis

(2012) Charlotte E Teunissen et al.   Multiple Sclerosis Journal

Ibudilast in relapsing-remitting multiple sclerosis: A neuroprotectant?

(2010) F. Barkhof et al.   NEUROLOGY

Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease

(2009) P Rolan et al.   EXPERT OPINION ON PHARMACOTHERAPY